Comparative Pharmacology
Head-to-head clinical analysis: LEVATOL versus PROPRANOLOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVATOL versus PROPRANOLOL HYDROCHLORIDE.
LEVATOL vs PROPRANOLOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Labetalol is a nonselective beta-adrenergic antagonist with additional alpha1-adrenergic blocking activity. It competitively blocks beta1 and beta2 receptors and alpha1 receptors, leading to decreased heart rate, myocardial contractility, and systemic vascular resistance.
Non-selective beta-adrenergic receptor antagonist that blocks catecholamine effects at beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure; also suppresses renin release and decreases sympathetic outflow.
50 mg orally once daily, increasing to 100 mg once daily after 2 weeks if tolerated; maximum 200 mg once daily.
Adults: 40 mg orally twice daily, increased gradually to 160-320 mg/day divided into 2-3 doses; maximum 640 mg/day. For hypertension: 80 mg orally twice daily, titrated to 120-240 mg/day. For migraine prophylaxis: 80 mg orally daily in divided doses, up to 160-240 mg/day. For angina: 80-320 mg orally divided into 2-4 doses. For essential tremor: 40 mg orally twice daily, up to 320 mg/day. For thyrotoxicosis: 10-40 mg orally every 6 hours. For IV use: 1-3 mg slow IV bolus (1 mg/min), repeated every 2-5 minutes up to total of 5 mg under continuous monitoring.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours; prolonged to 10-16 hours in severe renal impairment (CrCl <30 mL/min).
3-6 hours (terminal half-life), prolonged in hepatic impairment (up to 10-12 hours) and in elderly; half-life ~1-2 hours after IV administration; clinically, twice-daily dosing is sufficient due to sustained pharmacodynamic effect despite short half-life.
Renal excretion accounts for 55-60% as unchanged drug; biliary/fecal elimination accounts for 40-45% as metabolites and unchanged drug.
Hepatic metabolism (extensive first-pass) to inactive metabolites; <1% excreted unchanged in urine; renal elimination of metabolites (~90% as glucuronide and sulfate conjugates); biliary/fecal elimination minimal.
Category C
Category C
Beta-Blocker
Beta-Blocker